Evidence map›Paper›PMID 30510416›Full record

ArticleInternational journal of nanomedicine2018

Gelatin-epigallocatechin gallate nanoparticles with hyaluronic acid decoration as eye drops can treat rabbit dry-eye syndrome effectively via inflammatory relief.

Hsin-Yi Huang, Ming-Chen Wang, Zhi-Yu Chen, Wen-Ying Chiu, Ko-Hua Chen, I-Chan Lin, Wei-Chung Vivian Yang, Chi-Chang Wu, Ching-Li Tseng

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of nanomedicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 50 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
50citing papers in PubMed, 3 pooled it
9.6field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

50 citing papers in PubMed, 3 syntheses or guidelines pooled it, 111 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Review
  6. Mucoadhesive micelles for ophthalmic drug delivery.Journal of biomaterials applications · 2026
    Article
  7. Review
  8. Review
  9. Review
  10. Article
  11. Article
  12. Review
  13. Review
  14. Review
  15. Article
  16. Review
  17. Article
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 5 institutions in 1 country.

Hsin-Yi HuangGraduate Institute of Biomedical Materials and Tissue Engineering, College of Biomedical Engineering, Taipei Medical University, Taipei City, Taiwan, chingli@tmu.edu.tw.
Ming-Chen WangDepartment of Biomedical Engineering, Chung Yuan Christian University, Taoyuan City, Taiwan.
Zhi-Yu ChenGraduate Institute of Biomedical Materials and Tissue Engineering, College of Biomedical Engineering, Taipei Medical University, Taipei City, Taiwan, chingli@tmu.edu.tw.
Wen-Ying ChiuGraduate Institute of Biomedical Materials and Tissue Engineering, College of Biomedical Engineering, Taipei Medical University, Taipei City, Taiwan, chingli@tmu.edu.tw.
Ko-Hua ChenDepartment of Ophthalmology, Taipei Veterans General Hospital, Taipei City, Taiwan.
I-Chan LinDepartment of Ophthalmology, School of Medicine, College of Medicine, Taipei Medical University, Taipei City, Taiwan.
Wei-Chung Vivian YangPhD Program for Translational Medicine, College of Medical Science and Technology, Taipei Medical University, Taipei City, Taiwan.
Chi-Chang WuDepartment of Electronic Engineering, Feng Chia University, Taichung City, Taiwan.
Ching-Li TsengGraduate Institute of Biomedical Materials and Tissue Engineering, College of Biomedical Engineering, Taipei Medical University, Taipei City, Taiwan, chingli@tmu.edu.tw.
Taipei Medical University · TWChung Yuan Christian University · TWFeng Chia University · TWTaipei Medical University-Shuang Ho Hospital · TWTaipei Veterans General Hospital · TW

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionDry-eye syndrome (DES) is a general eye disease. Eye drops are the common ophthalmological medication. However, the ocular barrier makes it difficult to attain high drug bioavailability. Nanomedicine is a promising alternative treatment for ocular diseases and may increase drug content in the affected eye.

methodsTo explore this potential, we constructed nanoparticles (NPs) containing an anti-inflammatory agent for DES treatment. The NPs were made of gelatin-epigallocatechin gallate (EGCG) with surface decoration by hyaluronic acid (HA) and designated "GEH". The particle size, surface charge, and morphology were evaluated. The in vitro biocompatibility and anti-inflammation effect of nanoparticles were assayed via culturing with human corneal epithelium cells (HCECs) and in vivo therapeutic effect was examined in a DES rabbit's model.

resultsThe synthesized GEH NPs had a diameter of approximately 250 nm and were positively charged. A coculture experiment revealed that 20 µg/mL GEH was not cytotoxic to HCECs and that an EGCG concentration of 0.2 µg/mL downregulated the gene expression of

conclusionWe successfully produced GEH NPs with high affinity for HCECs and animal eyes. The treatment can be delivered as eye drops, which retain the drug on the ocular surface for a longer time. Ocular inflammation was effectively inhibited in DES rabbits. Therefore, GEH NPs are potentially valuable as a new therapeutic agent delivered in eye drops for treating DES.

Indexed as

AnimalsCatechinCell SurvivalCytokinesDisease Models, AnimalDry Eye SyndromesEpithelial CellsEpithelium, CornealGelatinHumansHyaluronic AcidInflammationMaleNanoparticlesOphthalmic SolutionsParticle SizeCatechinCytokinesepigallocatechin gallateGelatinHyaluronic AcidOphthalmic Solutionsanti-inflammationDESdry-eye syndromeEGCGepigallocatechin gallategelatin nanoparticlesHAhyaluronic acid

Identifiers

PMID30510416
PMCPMC6231513
OpenAlexW2899818668

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.